Manalo, Meljie M.
HRN: 20-44-34 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/13/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
09/13/2023
09/20/2023
IV
200mg
Q 8hrs
Subperiosteal Abscess
Waiting Final Action
Indication: Empiric Type of Infection: Eye, Ear, Nose, Throat, & Mouth Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes